Replies to post #60581 on PharmaCyte Biotech Inc (PMCB)

[frosr6]

The only "milestone" payments would be from PMCB to Austrianova. I've refrained from commenting since I was long but these misleading posts are a joke. Oh no position now btw since pmcb is bombarding shareholders with selling 100's millions in stock.
READ
(Cancer Licensing Agreement)
The Third Addendum requires the Company (PharmaCyte) to pay SG Austria, pursuant to a manufacturing agreement between the parties, a one-time manufacturing setup fee in the amount of $633,144.05 of which 50% is required to be paid on the signing of the manufacturing agreement and 50% is required to be paid three months later. In addition, the Third Addendum requires the Company to pay a fee for producing the final encapsulated cell product of $633.14 per vial of 300 capsules after production with a minimum purchased batch size of 400 vials of any Cell-in-a-Box® product.

The Third Addendum is an outright purchase. The Third Addendum requires the Company to make future royalty and milestone payments as follows:

· Two percent royalty on all gross sales received by the Company or its affiliates;

· Ten percent royalty on gross revenues received by the Company or its affiliates from any sublicense or right to use the patents or the licenses granted by the Company or its affiliates;

· Milestone payments of $100,000 due 30 days after enrollment of the first human patient in the first clinical trial for each product; $300,000 due 30 days after enrollment of the first human patient in the first Phase 3 clinical trial for each product; and $800,000 due 60 days after having a NDA or a BLA approved by the FDA or a MAA approved in Europe or its equivalent based on the country in which it is accepted for each product; and

· Milestone payments of $50,000 due 30 days after enrollment of the first veterinary patient in the first trial for each product and $300,000 due 60 days after having a BLA, a NDA or a MAA or its equivalent approved based on the country in which it is accepted for each veterinary product.
https://www.sec.gov/Archives/edgar/data/1157075/000101968714002942/nuvilex_10k-043014.htm

[frosr6]

Oh and here is the Diabetes one.
READ
The Diabetes Licensing Agreement requires the Company (PharmaCyte) to pay Austrianova Singapore, pursuant to a manufacturing agreement between the parties, a one-time manufacturing setup fee in the amount of $633,144, of which 50% is required to be paid on the signing of a manufacturing agreement and 50% is required to be paid three months later. In addition, the Diabetes Licensing Agreement requires the Company to pay a fee for producing the final encapsulated cell product of $633.14 per vial of 300 capsules after production with a minimum purchased batch size of 400 vials of any Cell-in-a-Box® product. 
The Diabetes Licensing Agreement requires the Company to make future royalty and milestone payments as follows:
Ten percent royalty of the gross sale of all products sold by the Company; ·
Twenty percent royalty of the amount actually received by the Company from sub-licensees on sub-licensees’ gross sales value; and ·
Milestone payments of $100,000 within 30 days of beginning the first pre-clinical experiments using the encapsulated cells; $500,000 within 30 days after enrollment of the first human patient in the first clinical trial; $800,000 within 30 days after enrollment of the first human patient in the first Phase 3 clinical trial; and $1,000,000 due 60 days after having a NDA or a BLA approved at the FDA or a MAA approved in Europe or its equivalent based on the country in which it is accepted for each product.
 
The license under the Diabetes Licensing Agreement may be terminated and all rights will revert to Austrianova Singapore if any of the following milestone events do not occur within the following timeframes: ·
If the Company does not enter into a research program with technology in the scope of the license involving European academic university partners providing a total funding equal to or greater than $400,000 within three years of the effective date of the Diabetes Licensing Agreement; or ·
If the Company does not enter into a clinical trial or its equivalent for a product within seven years of the effective date of the Diabetes Licensing Agreement.